



IFW  
1632

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/679,081	
	Filing Date	10/03/2003	
	First Named Inventor	Hans-Michael Dosch	
	Art Unit	1632	
	Examiner Name		
Total Number of Pages in This Submission	7	Attorney Docket Number	2560.001

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to a Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Copies of (41) references
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Ferris H. Lander McHale & Slavin, P.A.
Signature	<i>Ferris H. Lander</i>
Date	6/11/2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 6-11-2004			
Typed or printed	Debra N. Gerstemeier		
Signature	<i>[Signature]</i>	Date	6-11-2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN RE APPLICANT : Hans-Michael Dosch et al

INVENTION : PREVENTION OF PRIMARY SJOGREN'S  
SYNDROME BY ICA69 DEFICIENCY

SERIAL NUMBER : 10/679,081

FILING DATE : October 3, 2003

EXAMINER : (unassigned)

GROUP ART UNIT : 1632


ATTORNEY DOCKET NO. : 2560.001

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

CERTIFICATE UNDER 37 CFR §1.8(a)  
I hereby certify that this correspondence is being deposited with  
the U.S. Postal Service as First Class mail in an envelope  
addressed to Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450 on 6-11-2004



Pursuant to the Duty to Disclose under 37 CFR §1.56, the references cited on the accompanying form PTO/SB/08A and PTO/SB/08B are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The first (7) references were cited in an International Search Report issued in corresponding International Patent Application No. PCT/CA03/01535.

Applicants submit that the present invention is patentable over these references.

Respectfully submitted,

Date 6/10/2004

By Ferris H. Lander  
Ferris H. Lander  
Registration No. 43,377  
McHale & Slavin, P.A.  
2855 PGA Boulevard  
Palm Beach Gardens, FL 33410  
Telephone: (561) 625-6575  
Facsimile: (561) 625-6572

PTO/SB/08A (08-03)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/679,081
				Filing Date	10/3/2003
				First Named Inventor	Hans-Michael Dosch
				Art Unit	1632
				Examiner Name	
Sheet	2	of	5	Attorney Docket Number	2560.001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		S. WINER et al, "ICA69null nonobese diabetic mice develop diabetes, but resist disease acceleratino by cyclophosphamide", Journal of Immunology, 168(1):475-482 (January, 2002)	
		S. MARTIN et al, "Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis", Diabetologia, 38(3):351-355 (March, 1995)	
		S. WINER et al, "ICA69null NOD congenic mice are protected from sialitis and cyclophosphamide-accelerated diabetes", Diabetes, 50(Supp 2):A503 (June, 2001) Abstract XP008028882, 2114-PO	
		K. YANAGI et al, "Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NDO mouse model of Sjogren's syndrome", Eur. J. Immunol., 28(10):3336-3345 (October, 1998)	
		S. WINER et al, "Primary Sjogren's syndrome and deficiency of ICA69", The Lancet, 360(9339):1063-1069 (October, 2002)	
		R. FOX et al, "Update in Sjogren syndrome", Current Opinion in Rheumatology, 12:391-398 (2000)	
		J. JAMES et al, "Role of viruses in systemic lupus erythematosus and Sjogren syndrome", Current Opinion in Rheumatology, 13:370-376 (2001)	
		R. FOX et al, "Current issues in the diagnosis and treatment of Sjogren's syndrome", Current Opinion in Rheumatology, 11(5):364-371 (September, 1999)	
		J. HARLEY et al, "Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjogren's syndrome", Arthritis and Rheumatism, 29(2):196-206 (February, 1986)	
		O. BILLAUT-MULOT et al, "SS-56, a novel cellular target of autoantibody responses in Sjogren syndrome and systemic lupus erythematosus", The Journal of Clinical Investigation, 108(6):861-869 (September, 2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/679,081		
		Filing Date	10/3/2003		
		First Named Inventor	Hans-Michael Dosch		
		Art Unit	1632		
		Examiner Name			
Sheet	3	of	5	Attorney Docket Number	2560.001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		N. HANEJI et al, "Identification of alpha-Fodrin as a candidate autoantigen in primary Sjogren's syndrome", Science, 276:604-607 (April, 1997)	
		M. KUWANA et al, "Autoantibodies to the amino-terminal fragment of beta-Fodrin expressed in glandular epithelial cells in patients with Sjogren's syndrome", The Journal of Immunology, 167:5449-5456 (2001)	
		C. ROBINSON et al, "Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome", Proc. Natl. Acad. Sci. USA, 95:7538-7543 (June, 1998)	
		M. HUMPHREYS-BEHER et al, "Utilization of the non-obese diabetic (NOD) mouse as an animal model for the study of secondary Sjogren's syndrome", Adv. Exp. Med. Biol., 350:631-636 (1994)	
		R. HOFFMAN et al, "Sjogren's syndrome in MRL/l and MRL/n mice", Arthritis and Rheumatism, 27(2):157-165 (February, 1984)	
		N. HANEJI et al, "A new animal model for primary Sjogren's syndrome in NFS/sld mutant mice", The Journal of Immunology, 153:2769-2777 (1994)	
		J. BRAYER et al, "Sjogren's syndrome: immunological response underlying the disease", Arch. Immunol. Ther. Exp., 49:353-360 (2001)	
		C. ROBINSON et al, "A novel NOD-derived murine model of primary Sjogren's syndrome", Arthritis & Rheumatism, 41(1):150-156 (January, 1998)	
		W. KARGES et al, "Loss of self-tolerance to ICA69 in nonobese diabetic mice", Diabetes, 46:1548-1556 (October, 1997)	
		H.-MICHAEL DOSCH et al, "Persistent T cell anergy in human type 1 diabetes", The Journal of Immunology, 163:6933-6940 (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				<b>Application Number</b>	10/679,081
				<b>Filing Date</b>	10/3/2003
				<b>First Named Inventor</b>	Hans-Michael Dosch
				<b>Art Unit</b>	1632
				<b>Examiner Name</b>	
<b>Sheet</b>	4	of	5	<b>Attorney Docket Number</b>	2560.001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		M. PILON et al, "The diabetes autoantigen ICA69 and its Caenorhabditis elegans homologue, ric-19, are conserved regulators of neuroendocrine secretion", Molecular Biology of the Cell, 11:3277-3288 (October, 2000)	
		S. WINER et al, "ICA69 null nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide", The Journal of Immunology, 168:475-482 (2002)	
		W. KARGES et al, "Gene expression of islet cell antigen p69 in human, mouse, and rat", Diabetes, 45:513-521 (April, 1996)	
		S. WINER et al, "Type 1 diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis", The Journal of Immunology, 166:2831-2841 (2001)	
		D. SERREZE et al, "B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new 'speed congenic' stock of NOD.lgmu null mice", J. Exp. Med., 184:2049-2053 (November, 1996)	
		S. WINER et al, "Peptide dose, MHC affinity, and target self-antigen expression are critical for effective immunotherapy of nonobese diabetic mouse prediabetes", The Journal of Immunology, 165:4086-4094 (2000)	
		H.-M. DOSCH et al, "Measurement of T-cell autoreactivity in autoimmune diabetes", Diabetologia, 43:386-387 (2000)	
		R. HUNGER et al, "Male gonadal environment paradoxically promotes dacryoadenitis in nonobese diabetic mice", J. Clin. Invest., 101(6):1300-1309 (March, 1998)	
		W. CHEN et al, "Evidence that a peptide spanning the B-C junction of proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes", The Journal of Immunology, 167:4926-4935 (2001)	
		C. LAFITTE et al, "Neurological complications of primary Sjogren's syndrome", Journal of Neurology, 248(7):577-584 (July, 2001)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/679,081		
		Filing Date	10/3/2003		
		First Named Inventor	Hans-Michael Dosch		
		Art Unit	1632		
		Examiner Name			
Sheet	5	of	5	Attorney Docket Number	2560.001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		A. ANDONOPOULOS et al, "The spectrum of neurological involvement in Sjogren's syndrome", The British Journal of Rheumatology, 29:21-23 (1990)	
		K. MALINOW et al, "Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjogren's syndrome", Ann. Neurol., 20:535-537 (1986)	
		T. CHUSED et al, "Sjogren's syndrome association with HLA-Dw3", N. Engl. J. Med., 296(16):895-897 (April, 1977)	
		H. FOSTER et al, "Linkage studies of HLA and primary Sjogren's syndrome in multicase families", Arthritis and Rheumatism, 36(4):473-484 (April, 1993)	
		E. GOILLOT et al, "Sialadenitis in nonobese diabetic mice: transfer into syngeneic healthy neonates by splenic T lymphocytes", Clin. Immunol. Immunopathol., 59:462-473 (1991)	
		K. YANAGI et al, "Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NDO mouse model of Sjogren's syndrome", Eur. J. Immunol., 28:3336-3345 (1998)	
		R. MASAGO et al, "Elevated Proapoptotic Bax and Caspase 3 activation in the NOD.scid model of Sjogren's syndrome", Arthritis & Rheumatism, 44(3):693-702 (March, 2001)	
		C. ROBINSON et al, "Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadentitis of NOD mice", Clin. Immunol. Immunopathol., 79(1):50-59 (April, 1996)	
		J. GROOM et al, "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome", The Journal of Clinical Investigation, 109(1):59-68 (January, 2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.